News

SEMA4 PRESS RELEASE | 10.25.18

New Hope for Drug Discovery in Schizophrenia, Other Diseases with Improved Screening Models

“Scientists from the Icahn School of Medicine at Mount Sinai, Eli Lilly and Company, and Sema4 released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods. These findings could pave the way for streamlined drug discovery, particularly for diseases such as schizophrenia that have seen little therapeutic innovation…”
READ MORE
TECH NATION | 10.02.18

All That Personal Medical Data

“Take Alzheimer’s or heart disease, there may be a hundred different causes or pathways at play that may be affected in you… but completely different ones that affect another person with the same disease. It is about ultimately personalizing medicine in a precise way that is highly accurate, taking all the information into account, giving the most actionable guidance on what you should do to correct the problem…”
READ MORE
CBS | 10.01.18

Testing Babies: Do Parents Have Too Much Information About Their Kids?

“Every parent worries when it comes to the health of their child. Now, a simple test can give mothers and fathers a glimpse into their infant’s medical future…”
READ MORE
SEMA4 PRESS RELEASE | 08.21.18

Sema4 Applies Data-Driven Approach to Develop and Launch New NIPT and Expanded Carrier Screen Tests

“Sema4 today announced the launch of two reproductive health tests: the new Sema4 Noninvasive Prenatal Select and an enhanced version of its Expanded Carrier Screen. These products, developed with an informatics-driven approach using Sema4’s Health Intelligence Platform (SHIP), add to the company’s industry-leading portfolio of tests designed to support providers and patients from preconception to pediatrics…”
READ MORE
BLOOMBERG | 06.19.18

Data is Key to Medical Care

“At Sema4, we focus on delivering state of the art testing on patients in their normal health course. So, think of genomic testing, carrier screening, non-invasive prenatal testing, somatic tumor profiling. And, as we’re providing that state of the art testing, we are also aggregating lots of information around them regarding their condition, their electronic medical record, and even collecting information off devices, basically to better interpret the state of that individual, what kind of care they should receive, and what kind of disease or conditions they are at risk for…”
READ MORE
BBC | 05.25.18

Interview with Eric Schadt for BBC Tomorrow’s World

“Data can potentially be life-saving. It’s not all these worries and fears that we need to be thinking about when it comes to how we donate our personal information. Sometimes it can be used to crack cases, sometimes it can be used to improve our health. Medical data can be used for wonderful things…”
READ MORE
WTNH.COM | 04.26.18

Want to Know More About Your Newborn’s Health Early On?

“Connecticut mandates that newborns are screened for more than 50 disorders. But for parents who want to know more, there’s now a screening test available for more than three times as many. Every caring parent worries about a baby’s health. Now those who want more insight early on can get it. There’s a supplemental newborn screening test available, Natalis, developed by Sema4, a Stamford based health information company…”
READ MORE
GLOBAL GENES RARECAST | 03.22.18

Casting a Wider Net for Genetic Diseases

“While breakthroughs in the ability to diagnose newborns with genetic diseases continues to expand in scope and fall in cost, the extent of newborn screening varies state-by-state. Nevertheless, the improving affordability of newborn screening is expanding access to these tests for parents seeking them. We spoke to Eric Schadt, CEO of Sema4, about the changing landscape for newborn screening, the company’s Natalis test, and how far off we are from routine screening of newborns with comprehensive genetic sequencing…”
READ MORE
STAMFORD ADVOCATE | 03.11.18

Sema4 Aims to Advance Newborn Testing With Latest Product

“Newborns in the U.S. are usually tested for about three dozen diseases. But that number only scratches the surface of potential illnesses, says genomic-testing firm Sema4. Aiming to fill the gaps between the scope of traditional tests and the thousands of disorders that can afflict young children, Stamford-based Sema4 launched last month an at-home test for 193 conditions that manifest in childhood…”
READ MORE
SEMA4 PRESS RELEASE | 02.28.18

Poll Finds Most Americans Want to Know About Their Baby’s Genetic Risk for Treatable Childhood Disorders

“Sema4 today announced the results of a public opinion poll of among more than 2,000 Americans about newborn genetic screening. According to the survey, commissioned by Sema4 and conducted online by Harris Poll, 88% of Americans say that if they were new parents and could find out just after their baby is born about their child’s genetic risk of getting a treatable early onset disease, they would want to know…”
READ MORE